B
L. E. Bermudez, Young, L. S., and Enkel, H.,
“Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins.”,
Infection and immunity, vol. 59, no. 5, pp. 1697-702, 1991.
L. E. Bermudez and Inderlied, C. B.,
“Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.”,
Microbial drug resistance (Larchmont, N.Y.), vol. 3, no. 3, pp. 277-82, 1997.
L. E. Bermudez, Kemper, C. A., and Deresinski, S. C.,
“Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF.”,
Biotherapy (Dordrecht, Netherlands), vol. 8, no. 2, pp. 135-42, 1994.
L. E. Bermudez, Wagner, D., and Sosnowska, D.,
“Mechanisms of Mycobacterium avium pathogenesis.”,
Archivum immunologiae et therapiae experimentalis, vol. 48, no. 6, pp. 521-7, 2000.
L. E. Bermudez, Wu, M., Young, L. S., and Inderlied, C. B.,
“Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.”,
The Journal of infectious diseases, vol. 166, no. 4, pp. 923-6, 1992.
L. E. Bermudez, Petrofsky, M., and Stevens, P.,
“Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.”,
Immunology, vol. 94, no. 3, pp. 297-303, 1998.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor.”,
Lymphokine research, vol. 9, no. 2, pp. 137-45, 1990.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Chee, C. B., Aralar, P., Petrofsky, M., Parman, T., Green, C. E., Lewin, A. H., Ellis, W. Y., and Young, L. S.,
“Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice.”,
Antimicrobial agents and chemotherapy, vol. 56, no. 8, pp. 4202-6, 2012.
L. E. Bermudez, Young, L. S., and Inderlied, C. B.,
“Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S.,
“Naturally occurring antibodies against Mycobacterium avium complex.”,
Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, Sangari, F. J., Kolonoski, P., Petrofsky, M., and Goodman, J.,
“The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells.”,
Infection and immunity, vol. 70, no. 1, pp. 140-6, 2002.
L. E. Bermudez, Shelton, K., and Young, L. S.,
“Comparison of the ability of Mycobacterium avium, M. smegmatis and M. tuberculosis to invade and replicate within HEp-2 epithelial cells.”,
Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol. 76, no. 3, pp. 240-7, 1995.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S.,
“SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.”,
Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez, Kolonoski, P., Young, L. S., and Inderlied, C. B.,
“Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1844-8, 1994.